JPWO2020055812A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020055812A5 JPWO2020055812A5 JP2021538170A JP2021538170A JPWO2020055812A5 JP WO2020055812 A5 JPWO2020055812 A5 JP WO2020055812A5 JP 2021538170 A JP2021538170 A JP 2021538170A JP 2021538170 A JP2021538170 A JP 2021538170A JP WO2020055812 A5 JPWO2020055812 A5 JP WO2020055812A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- seq
- amino acid
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000001413 amino acids Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 5
- 238000011191 terminal modification Methods 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 101150104494 CAV1 gene Proteins 0.000 claims 1
- 102000003727 Caveolin 1 Human genes 0.000 claims 1
- 108090000026 Caveolin 1 Proteins 0.000 claims 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024031305A JP7737492B2 (ja) | 2018-09-10 | 2024-03-01 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| JP2025142971A JP2025184877A (ja) | 2018-09-10 | 2025-08-29 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728997P | 2018-09-10 | 2018-09-10 | |
| US62/728,997 | 2018-09-10 | ||
| PCT/US2019/050332 WO2020055812A1 (en) | 2018-09-10 | 2019-09-10 | Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031305A Division JP7737492B2 (ja) | 2018-09-10 | 2024-03-01 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500078A JP2022500078A (ja) | 2022-01-04 |
| JPWO2020055812A5 true JPWO2020055812A5 (https=) | 2022-09-06 |
| JP2022500078A5 JP2022500078A5 (https=) | 2022-09-06 |
| JP7496826B2 JP7496826B2 (ja) | 2024-06-07 |
Family
ID=69778115
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538170A Active JP7496826B2 (ja) | 2018-09-10 | 2019-09-10 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| JP2024031305A Active JP7737492B2 (ja) | 2018-09-10 | 2024-03-01 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| JP2025142971A Pending JP2025184877A (ja) | 2018-09-10 | 2025-08-29 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031305A Active JP7737492B2 (ja) | 2018-09-10 | 2024-03-01 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
| JP2025142971A Pending JP2025184877A (ja) | 2018-09-10 | 2025-08-29 | Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11905336B2 (https=) |
| EP (1) | EP3849580A4 (https=) |
| JP (3) | JP7496826B2 (https=) |
| CN (2) | CN112739367B (https=) |
| AU (2) | AU2019339260B2 (https=) |
| BR (1) | BR112021004404A2 (https=) |
| CA (1) | CA3111563A1 (https=) |
| WO (1) | WO2020055812A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201144B (zh) | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
| WO2020185826A1 (en) * | 2019-03-11 | 2020-09-17 | Lung Therapeutics, Inc. | Compositions and methods for protecting type 2 alveolar epithelial cells (aec2) |
| US20230159608A1 (en) * | 2020-04-21 | 2023-05-25 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and uses thereof |
| US20230226149A1 (en) * | 2020-06-19 | 2023-07-20 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury |
| US20250076312A1 (en) * | 2021-02-25 | 2025-03-06 | Lung Therapeutics, Llc | Biomarkers for the treatment of interstitial lung disease |
| US20250041383A1 (en) * | 2021-06-17 | 2025-02-06 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of post-acute covid-19 |
| US20250262273A1 (en) * | 2021-10-22 | 2025-08-21 | Rein Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of chronic kidney disease |
| CN119661656A (zh) * | 2024-11-20 | 2025-03-21 | 华中科技大学同济医学院附属梨园医院 | 一种靶向拮抗pCAV1的多肽及其应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021387A (en) | 1975-11-19 | 1977-05-03 | President And Fellows Of Harvard College | Eosinophilotactic tetrapeptides |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
| US4816449A (en) | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
| US4613676A (en) | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
| ZA846192B (en) | 1984-08-09 | 1986-03-26 | Merck Patent Gmbh | Immunotherapeutic polypeptide agents |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| DK53291D0 (da) | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
| US5938117A (en) | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
| US6629646B1 (en) | 1991-04-24 | 2003-10-07 | Aerogen, Inc. | Droplet ejector with oscillating tapered aperture |
| US6540154B1 (en) | 1991-04-24 | 2003-04-01 | Aerogen, Inc. | Systems and methods for controlling fluid feed to an aerosol generator |
| US5277175A (en) | 1991-07-12 | 1994-01-11 | Riggs John H | Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir |
| GB9120005D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
| US5355872B1 (en) | 1992-03-04 | 1998-10-20 | John H Riggs | Low flow rate nebulizer apparatus and method of nebulization |
| US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| CN1091138A (zh) | 1992-08-27 | 1994-08-24 | 迪金研究有限公司 | 疫苗 |
| JP3401005B2 (ja) | 1992-12-11 | 2003-04-28 | ユニバーシティ オブ フロリダ | 有害生物の防除のための材料および方法 |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| WO1997009085A1 (en) | 1995-09-06 | 1997-03-13 | Ryder Steven L | Variable oxygen concentration high-flow nebulizer |
| US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
| ES2140998B1 (es) | 1996-05-13 | 2000-10-16 | Univ Sevilla | Procedimiento de atomizacion de liquidos. |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
| US20030113271A1 (en) | 1997-01-29 | 2003-06-19 | University Technology Corporation | Formulations for pulmonary delivery |
| IT1291122B1 (it) | 1997-03-28 | 1998-12-29 | Sar Spa | Micropompa per la nebulizzazione di fluidi con valvola dosatrice perfezionata |
| US6096707A (en) | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
| US6044841A (en) | 1997-08-29 | 2000-04-04 | 1263152 Ontario Inc. | Breath actuated nebulizer with valve assembly having a relief piston |
| US6041776A (en) | 1998-05-14 | 2000-03-28 | Briggs, Iii; Stephen W. | Medical nebulization device |
| US6354516B1 (en) | 1999-11-02 | 2002-03-12 | Aradigm Corporation | Pore structures for reduced pressure aerosolization |
| SE9900369D0 (sv) | 1999-02-04 | 1999-02-04 | Siemens Elema Ab | Ultrasonic nebuliser |
| US6328030B1 (en) | 1999-03-12 | 2001-12-11 | Daniel E. Kidwell | Nebulizer for ventilation system |
| EP1076091A1 (en) | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| WO2002009798A1 (en) | 2000-08-02 | 2002-02-07 | Research Development Foundation | Jet nebulizer assembly for home administration of drugs in aerosols |
| US20020077283A1 (en) | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
| US6732944B2 (en) | 2001-05-02 | 2004-05-11 | Aerogen, Inc. | Base isolated nebulizing device and methods |
| GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| EP1471960B1 (en) | 2002-01-07 | 2019-03-13 | Novartis AG | Devices for nebulizing fluids for inhalation |
| EP1474196B1 (en) | 2002-01-15 | 2016-08-17 | Novartis AG | Methods and systems for operating an aerosol generator |
| AU2003237798A1 (en) | 2002-04-05 | 2003-10-27 | Board Of Regents, The University Of Texas System | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
| EP1501479A1 (en) | 2002-05-07 | 2005-02-02 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same |
| US20040175384A1 (en) | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US7625865B2 (en) | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| CN101022830A (zh) | 2004-05-25 | 2007-08-22 | 阿特努奥恩公司 | 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途 |
| BRPI0611198B1 (pt) | 2005-05-25 | 2018-02-06 | Aerogen, Inc. | Vibration systems and methods |
| TWI299993B (en) | 2005-12-15 | 2008-08-21 | Dev Center Biotechnology | Aqueous inhalation pharmaceutical composition |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP2074142A4 (en) * | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| US20090068258A1 (en) | 2007-08-28 | 2009-03-12 | Lisanti Michael P | Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy |
| CN102131827A (zh) | 2007-12-13 | 2011-07-20 | 葛兰素集团有限公司 | 用于肺部传递给药的组合物 |
| WO2009111625A2 (en) | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| WO2009152453A2 (en) | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating pulmonary hypertension |
| JP5859307B2 (ja) | 2008-09-10 | 2016-02-10 | ジェネンテック， インコーポレイテッド | 眼の血管新生を阻害する方法 |
| EP2349314B1 (en) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| WO2010132864A1 (en) | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| MX2012003171A (es) | 2009-09-28 | 2012-04-11 | Hoffmann La Roche | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| PT3501499T (pt) | 2010-02-11 | 2022-11-22 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
| EP2635686B1 (en) * | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| EP3725892A1 (en) | 2012-03-27 | 2020-10-21 | F. Hoffmann-La Roche AG | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
| WO2013184482A1 (en) | 2012-06-04 | 2013-12-12 | Yale University | Method of treating and preventing ocular angiogenesis |
| BR112015022831A2 (pt) | 2013-03-13 | 2017-08-22 | Forest Laboratories Holdings Ltd | Composições farmacêuticas micronizadas |
| CN110201144B (zh) | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| CN104274827B (zh) | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
| MX2016005720A (es) | 2013-11-04 | 2016-11-25 | Univ Texas | Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto. |
| WO2015080943A1 (en) * | 2013-11-26 | 2015-06-04 | Yale University | Novel cell-penetrating compositions and methods using same |
| WO2015080980A2 (en) * | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
| WO2016138413A1 (en) | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
| CN107216394B (zh) * | 2017-06-21 | 2020-10-09 | 江南大学 | 一种小窝蛋白-1脚手架区融合多肽的制备方法及其应用 |
| US20190224243A1 (en) | 2018-01-25 | 2019-07-25 | Musc Foundation For Research Development | Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains |
| KR20210057127A (ko) | 2018-09-10 | 2021-05-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
| US20240082342A1 (en) | 2018-11-21 | 2024-03-14 | Board Of Regents, The University Of Texas System | Peptide therapeutics for increasing lung cell viability |
| US20220370544A1 (en) | 2018-11-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Peptide therapeutics for acute and chronic airway and alveolar diseases |
| WO2020185826A1 (en) | 2019-03-11 | 2020-09-17 | Lung Therapeutics, Inc. | Compositions and methods for protecting type 2 alveolar epithelial cells (aec2) |
| US12097222B2 (en) | 2019-06-06 | 2024-09-24 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| CN111671886B (zh) | 2020-03-05 | 2022-11-15 | 上海甘翼生物医药科技有限公司 | 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途 |
| US20230159608A1 (en) | 2020-04-21 | 2023-05-25 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and uses thereof |
| US20230226149A1 (en) | 2020-06-19 | 2023-07-20 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury |
| US20250076312A1 (en) | 2021-02-25 | 2025-03-06 | Lung Therapeutics, Llc | Biomarkers for the treatment of interstitial lung disease |
| US12449810B2 (en) | 2021-03-01 | 2025-10-21 | The Boeing Company | Autonomous maneuver generation to mate connectors |
| US20250041383A1 (en) | 2021-06-17 | 2025-02-06 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of post-acute covid-19 |
| US20250262273A1 (en) | 2021-10-22 | 2025-08-21 | Rein Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of chronic kidney disease |
-
2019
- 2019-09-10 AU AU2019339260A patent/AU2019339260B2/en active Active
- 2019-09-10 CN CN201980059209.6A patent/CN112739367B/zh active Active
- 2019-09-10 BR BR112021004404-3A patent/BR112021004404A2/pt unknown
- 2019-09-10 CA CA3111563A patent/CA3111563A1/en active Pending
- 2019-09-10 CN CN202510609954.0A patent/CN121159628A/zh active Pending
- 2019-09-10 WO PCT/US2019/050332 patent/WO2020055812A1/en not_active Ceased
- 2019-09-10 US US17/274,721 patent/US11905336B2/en active Active
- 2019-09-10 JP JP2021538170A patent/JP7496826B2/ja active Active
- 2019-09-10 EP EP19859759.3A patent/EP3849580A4/en active Pending
-
2022
- 2022-12-21 US US18/069,541 patent/US11787838B2/en active Active
-
2023
- 2023-09-01 US US18/460,215 patent/US12497431B2/en active Active
-
2024
- 2024-03-01 JP JP2024031305A patent/JP7737492B2/ja active Active
-
2025
- 2025-08-29 JP JP2025142971A patent/JP2025184877A/ja active Pending
- 2025-09-19 AU AU2025234225A patent/AU2025234225A1/en active Pending
- 2025-11-13 US US19/388,100 patent/US20260062444A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500078A5 (https=) | ||
| EP2686431B1 (en) | Antagonists of the interleukin- 1 receptor | |
| CN108992661B (zh) | 一种多肽在制备静脉、腹腔或鼻腔给药药物中的应用 | |
| JP2012500001A5 (https=) | ||
| KR20170085611A (ko) | 변형된 혈관활성 장 펩티드 | |
| JP7621728B2 (ja) | プロテアーゼ活性化受容体２のモジュレーター | |
| JPWO2020055812A5 (https=) | ||
| JP2025122021A5 (https=) | ||
| CN109265558B (zh) | 改进型齐考诺肽在制备药物中的应用 | |
| CN111690071A (zh) | 一种具有靶向穿膜性的抗肿瘤多肽 | |
| CN109265557B (zh) | 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用 | |
| CN113383005A (zh) | 靶向线粒体疾病的类似物 | |
| CN109265556B (zh) | 一种适用于静脉、腹腔或鼻腔给药的多肽 | |
| CN109232744B (zh) | 改进型齐考诺肽 | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| CN113501862B (zh) | 一种多肽及其在制备免疫调节药物中的应用 | |
| JP2002543096A (ja) | ＴＧＦ−αポリペプチド、機能性断片およびそれらの利用法 | |
| CN114409733A (zh) | 靶向抑制mlkl乙酰化的多肽和/或其衍生物及其用途 | |
| JP7824885B2 (ja) | 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体 | |
| CN109232745B (zh) | 一种可通过血脑屏障的多肽 | |
| US20250059232A1 (en) | Pentapeptide and use thereof | |
| CN101671390A (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| CN115181186A (zh) | 一种抑制肿瘤侵袭转移的多肽组合及其应用 | |
| CN106061495B (zh) | 肺内炎症的减弱 | |
| CN116003528A (zh) | 靶向竞争性抑制CCL20结合整合素α5β1的多肽和/或其衍生物及应用 |